Verify the plan's formulary listing, tier price, coverage limits, and annual cap before paying for any sleep drug used in dementia. Also check safety guidance, because sedating drugs carry higher risk of confusion, falls, and decline in dementia.
Part D is Medicare's prescription-drug coverage. Each plan sets its own covered list and prices, so the same drug can cost very different amounts. Use the specific plan documents to confirm coverage before the pharmacy visit.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Which sleep drugs raise higher risk?
- What does your plan cover and charge?
- What rules can delay or deny payment?
- How do caps and cash prices affect decisions?
Which sleep drugs raise higher risk?
The American Geriatrics Society advises avoiding benzodiazepines, Z-drugs zolpidem, eszopiclone, and zaleplon, anticholinergics, and chronic antipsychotics in dementia, in its 2023 Beers Criteria update. Z-drugs are prescription sleep drugs. The Society links these drugs to thinking harm, stroke, faster decline, and death.
UCLA Newsroom, reporting a JAMA study, found one in four Medicare beneficiaries with dementia received brain-altering drugs linked to falls, confusion, and hospitalization. Benzodiazepine use fell from 11.4% to 9.1% in 2013-2021. UCLA Newsroom notes limits: missing Medicare Advantage data, possibly incomplete indications, and prescribing prevalence rather than total exposure.
What does your plan cover and charge?
Medicare.gov says Part D plans must cover most antidepressants, antipsychotics, and anticonvulsants. Each plan still keeps its own formulary, which is its covered-drug list, and its own tier prices, which are price levels.
Check the specific plan before assuming coverage. SingleCare reports Quviviq daridorexant costs about $649 for 30 tablets without insurance, has no generic, and is covered by only some Part D plans. That gap makes plan checking matter.
- exact drug name, strength, and quantity on the formulary
- tier price at preferred and non-preferred pharmacies
- whether refills need a new approval
What rules can delay or deny payment?
Medicare.gov says plans may require prior authorization, step therapy with a cheaper drug first, or quantity limits. Prior authorization means plan approval before payment.
Step therapy means trying a lower-cost drug first. Patients or prescribers can request a formulary or tier exception with medical justification. Keep the request tied to the person with dementia.
- ask the prescriber to state why the drug is needed
- file the formulary or tier exception in writing
- save the plan answer with the medication list
How do caps and cash prices affect decisions?
CMS states in its final Part D redesign instructions that annual out-of-pocket spending on covered drugs is capped at $2,000 in 2025 and $2,100 in 2026. Spending above the cap costs $0 for covered drugs. MyMedicarePlans, citing CMS rules, says over-the-counter sleep aids such as melatonin are excluded from Part D and do not count toward the cap.
Some Medicare Advantage plans offer limited OTC extras. SingleCare reports in its Belsomra price guide that Belsomra suvorexant costs about $633 monthly without insurance. SingleCare reports in its trazodone price guide that generic trazodone averages $24 for thirty 50-mg tablets and about $60 yearly with discounts. Bring the formulary printout and exception letter to the prescribing visit.
